新型前列腺癌显像剂 <sup>68 </sup>Ga-PSMA-4PY的初步临床研究

张晓军; 刘欢欢; 刘亚超; 王瑞民; 张锦明

doi:10.19732/j.cnki.2096-6210.2024.04.005

您当前的位置：

首页 >

文章列表页 >

新型前列腺癌显像剂 ⁶⁸Ga-PSMA-4PY的初步临床研究

专题论著 | 更新时间：2025-12-15

- 新型前列腺癌显像剂 ⁶⁸Ga-PSMA-4PY的初步临床研究
- Initial clinical study of a novel prostate cancer imaging agent, ⁶⁸ Ga-PSMA-4PY
- 肿瘤影像学 2024年33卷第4期页码：369-375
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19732/j.cnki.2096-6210.2024.04.005
  中图分类号：
- 网络出版：2024-09-12，
  
  纸质出版：2024-09-12
- 稿件说明：
移动端阅览
张晓军,刘欢欢,刘亚超,等. 新型前列腺癌显像剂 ⁶⁸Ga-PSMA-4PY的初步临床研究[J]. 肿瘤影像学, 2024, 33(4): 369-375 https://doi.

org/10.19732/j.cnki.2096-6210.2024.04.005
张晓军,刘欢欢,刘亚超,等. 新型前列腺癌显像剂 ⁶⁸Ga-PSMA-4PY的初步临床研究[J]. 肿瘤影像学, 2024, 33(4): 369-375 https://doi. DOI： 10.19732/j.cnki.2096-6210.2024.04.005.

org/10.19732/j.cnki.2096-6210.2024.04.005 DOI：

摘要

目的：

评估一种体内快速清除的前列腺癌显像剂 68 Ga-PSMA-4PY在临床应用中的潜力。

方法：

采用前体药盒化方法标记

Ga-PSMA-4PY，进行质量控制确保其纯度和安全性；通过动态正电子发射体层成像（positron emission tomography，PET）分析 68 Ga-PSMA-4PY在小鼠血液、肝脏和肾脏中的放射性摄取及清除。并通过临床显像研究比较

Ga-PSMA-4PY与

Ga-PSMA-11在前列腺癌患者体内的分布特性。

结果：

经前体药盒化标记的

Ga-PSMA-4PY具有良好的标记效率和稳定性。小鼠动态PET结果显示，

Ga-PSMA-4PY在血液中的清除特征与

Ga-PSMA-11相近；

Ga-PSMA-4PY在肾脏中的放射性摄取峰值出现在2 min内，并随后快速排出，而

Ga-PSMA-11在肾脏中呈持续性增加，直至60 min时达到

Ga-PSMA-4PY的11倍。临床研究表明，

Ga-PSMA-4PY可以在前列腺癌中浓集，在肝、肾和脾脏中的放射性滞留明显低于

Ga-PSMA-11，且唾液腺摄取降低了57.5%。

结论：

Ga-PSMA-4PY能够快速浓聚到PSMA阳性的肿瘤中，并迅速从正常组织中清除，将有助于减少非特异性摄取引起的不良反应，是一种具有良好前景的前列腺癌显像剂。

Abstract

Objective:

To evaluate the potential of

Ga-PSMA-4PY

a prostate cancer imaging agent characterized by rapid clearance from the body

for clinical application.

Methods:

The precursor was kit-labeled with

Ga-PSMA-4PY

nd quality control measures ensured its purity and safety. Dynamic positron emission tomography (PET) imaging was used to study the radiotracer uptake and clearance dynamics of

Ga-PSMA-4PY in the blood

liver

and kidneys of mice. Clinical imaging studies compared the distribution characteristics of 68 Ga-PSMA-4PY with those of

Ga-PSMA-11 in prostate cancer patients.

Results:

The kit-labeled 68 Ga-PSMA-4PY exhibited good labeling efficiency and stability. Dynamic PET imaging in mice revealed that the clearance profileof

Ga-PSMA-4PY in the blood was comparable to that of

Ga-PSMA-11. The renal radiotracer uptake of

Ga-PSMA-4PY peaked within 2 min and was rapidly cleared

whereas

Ga-PSMA-11 uptake in the kidneys increased continuously

reaching 11 times higher than that of

Ga-PSMA-4PY at 60 min. Clinical studies demonstrated that

Ga-PSMA-4PY accumulated in prostate cancer lesions

with significantly lower radiotracer retention in the liver

kidneys

and spleen compared to

Ga-PSMA-11

and a reduction of 57.5% in salivary gland uptake.

Conclusion:

Ga-PSMA-4PY can rapidly accumulate in PSMA-positive tumors and clear quickly from normal tissues

which will help reduce nonspecific uptake and associated side effects

making it a promising prostate cancer imaging agent.

关键词

Keywords

references

浏览量

251

下载量

CNKI被引量

文章被引用时，请邮件提醒。

提交

工具集

关联资源

利用¹⁸F-FDG PET显像评估不同治疗阶段前列腺癌的研究

靶向PSMA诊疗一体化：应用与进展

¹⁸ F-PSMA-1007 PET/CT和mpMRI在前列腺癌原发灶检测及病灶腺体内定位的对比研究

^99mTc-PSMA SPECT/CT探测前列腺癌病灶的临床应用价值

前列腺特异性膜抗原为靶标的放射免疫治疗进展

新型前列腺癌显像剂 68 Ga-PSMA-4PY的初步临床研究

Initial clinical study of a novel prostate cancer imaging agent, 68 Ga-PSMA-4PY

DOI：10.19732/j.cnki.2096-6210.2024.04.005

摘要

Abstract

关键词

Keywords

references

新型前列腺癌显像剂 ⁶⁸Ga-PSMA-4PY的初步临床研究

Initial clinical study of a novel prostate cancer imaging agent, ⁶⁸ Ga-PSMA-4PY